LDE-225 with Gemcitabine and Nab-Paclitaxel in Borderline Resectable Pancreatic Cancer

Phase 2, randomised, open-label trial of sonidegib in pancreatic ductal adenocarcinoma (PDAC) (5 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy as Measured by Number of Participants Who Tolerated the Maximal Dose of LDE-225 at 5 years and Resection Rate of Two Preoperative Chemotherapy Regimens in Patients With Borderline Resectable PDA at 5 years. Started Dec 2011; status: terminated.